$41.89
1.553.84%
At Close: -
$41.89
00.00%
After Hours: 4:19 PM EDT
15 minutes delayed
Janux Therapeutics
JANXNASDAQ
Janux Therapeutics (NASDAQ:JANX) Stock, Analyst Ratings, Price Targets, Predictions
Janux Therapeutics Inc has a consensus price target of $51.7, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from Scotiabank, HC Wainwright & Co., and Cantor Fitzgerald on May 30, 2024, May 13, 2024, and May 9, 2024. With an average price target of $70 between Scotiabank, HC Wainwright & Co., and Cantor Fitzgerald, there's an implied 67.10% upside for Janux Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
HC Wainwright & Co.
Cantor Fitzgerald
Wedbush
JonesTrading
1calculated from analyst ratings
Analyst Ratings for Janux Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/30/2024 | Buy Now | 12.2% | Scotiabank | George Farmer | → $47 | Initiates | → Sector Perform | Get Alert |
| 05/13/2024 | Buy Now | 50.39% | HC Wainwright & Co. | Swayampakula Ramakanth | $50 → $63 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 138.72% | Cantor Fitzgerald | Josh Schimmer | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 05/08/2024 | Buy Now | 76.65% | Wedbush | Robert Driscoll | $53 → $74 | Maintains | Outperform | Get Alert |
| 04/16/2024 | Buy Now | 67.1% | JonesTrading | Soumit Roy | → $70 | Initiates | → Buy | Get Alert |
| 03/21/2024 | Buy Now | 48.01% | BTIG | Kaveri Pohlman | → $62 | Initiates | → Buy | Get Alert |
| 03/20/2024 | Buy Now | 138.72% | Cantor Fitzgerald | Josh Schimmer | → $100 | Initiates | → Overweight | Get Alert |
| 03/13/2024 | Buy Now | 14.59% | B of A Securities | Geoff Meacham | $24 → $48 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 19.36% | HC Wainwright & Co. | Swayampakula Ramakanth | $35 → $50 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 26.52% | Wedbush | David Driscoll | $24 → $53 | Maintains | Outperform | Get Alert |
| 11/13/2023 | Buy Now | -16.45% | HC Wainwright & Co. | Swayampakula Ramakanth | → $35 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2023 | Buy Now | -42.71% | Wedbush | Robert Driscoll | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | -42.71% | Wedbush | Robert Driscoll | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | -16.45% | HC Wainwright & Co. | Swayampakula Ramakanth | → $35 | Reiterates | Buy → Buy | Get Alert |
| 07/18/2023 | Buy Now | -42.71% | Wedbush | Robert Driscoll | → $24 | Reiterates | Outperform → Outperform | Get Alert |
| 07/18/2023 | Buy Now | -16.45% | HC Wainwright & Co. | Swayampakula Ramakanth | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | -42.71% | Wedbush | Robert Driscoll | → $24 | Reiterates | → Outperform | Get Alert |
| 05/10/2023 | Buy Now | -16.45% | HC Wainwright & Co. | Swayampakula Ramakanth | → $35 | Reiterates | → Buy | Get Alert |
| 04/06/2023 | Buy Now | -42.71% | Wedbush | Robert Driscoll | → $24 | Initiates | → Outperform | Get Alert |
| 03/13/2023 | Buy Now | -16.45% | HC Wainwright & Co. | Swayampakula Ramakanth | → $35 | Reiterates | → Buy | Get Alert |
| 11/14/2022 | Buy Now | — | William Blair | Matt Phipps | — | Initiates | → Outperform | Get Alert |
| 07/06/2021 | Buy Now | -16.45% | B of A Securities | Geoff Meacham | — | Initiates | → Buy | Get Alert |
| 07/06/2021 | Buy Now | — | Cowen & Co. | Marc Frahm | — | Initiates | → Outperform | Get Alert |
| 07/06/2021 | Buy Now | -16.45% | HC Wainwright & Co. | Swayampakula Ramakanth | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Janux Therapeutics (JANX) stock?
The latest price target for Janux Therapeutics (NASDAQ:JANX) was reported by Scotiabank on May 30, 2024. The analyst firm set a price target for $47.00 expecting JANX to rise to within 12 months (a possible 12.20% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Janux Therapeutics (JANX)?
The latest analyst rating for Janux Therapeutics (NASDAQ:JANX) was provided by Scotiabank, and Janux Therapeutics initiated their sector perform rating.
When was the last upgrade for Janux Therapeutics (JANX)?
There is no last upgrade for Janux Therapeutics
When was the last downgrade for Janux Therapeutics (JANX)?
There is no last downgrade for Janux Therapeutics.
When is the next analyst rating going to be posted or updated for Janux Therapeutics (JANX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Janux Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Janux Therapeutics was filed on May 30, 2024 so you should expect the next rating to be made available sometime around May 30, 2025.
Is the Analyst Rating Janux Therapeutics (JANX) correct?
While ratings are subjective and will change, the latest Janux Therapeutics (JANX) rating was a initiated with a price target of $0.00 to $47.00. The current price Janux Therapeutics (JANX) is trading at is $41.89, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.